The Role of the Inflammatory Cascade in the Pathogenesis and Treatment of Psoriatic Arthritis: New and Emerging Therapies

 

Release Date: August 31, 2017

Last Reviewed: August 30, 2017

Expiration Date: August 31, 2018

 

Professor of Medicine

Chief, Division of Allergy/Immunology & Rheumatology

Director, Clinical Immunology Research Unit

University of Rochester Medical Center

University of Rochester School of Medicine and Dentistry

Rochester, NY

 

M. Elaine Husni, MD, MPH
Assistant Professor

Cleveland Clinic Lerner College of Medicine

Case Western Reserve University

Vice Chair of Rheumatology
Director of the Arthritis & Musculoskeletal Center
Cleveland Clinic
Cleveland, OH

 

Alexis R. Ogdie, MD, MSCE
Assistant Professor of Medicine

Assistant Professor of Epidemiology in Biostatistics and Epidemiology

Perelman School of Medicine at the University of Pennsylvania

Director, Penn Psoriatic Arthritis Clinic
Hospital of the University of Pennsylvania
Philadelphia, PA

This activity is provided by Indiana University School of Medicine.  Paradigm Medical Communications, LLC, is the educational partner. 
                                                                                               
 

This activity has been designed to address the educational needs of rheumatologists. It may also be of benefit to other healthcare professionals (HCPs) interested in optimal management of psoriatic arthritis.

 

The workings of the inflammatory cascade are not fully defined, but recent findings have demonstrated roles for novel inflammatory mediators, such as interleukin (IL)-17, IL-12/23, and phosphodiesterase 4 (PDE-4) in the pathophysiology of psoriatic arthritis (PsA). Manipulating these elements has led to the development of newly approved therapies for the treatment of PsA, including approvals for 5 of these unique agents in the past 3 years. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment guidelines were updated in 2015, and trial results continue to emerge. Rheumatologists lack knowledge of these newly reported inflammatory mechanisms and are therefore challenged to know how newly emerged therapies should fit into the PsA armamentarium; so, which agents are best suited to which patients and when. This activity will provide expert-led, case-based discussion of these newer inflammatory pathways, illustrated by an animated mechanism of action (MOA) video, to enable better informed and appropriate treatment plans that improve outcomes for patients with PsA.

 

Upon proper completion of this activity, participants should be better able to:

Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

 

Indiana University School of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please contact Indiana University School of Medicine at (317) 274-0104 or cme@iu.edu.com.
 

This activity is supported by educational grants from Celgene Corporation and Novartis Pharmaceuticals Corporation.

 

To receive a CME certificate of participation, you should:

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.

 

There is no fee required for participation in this activity.

This certified CME activity is designed using HTML5 video and audio.
 

Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher.

 

iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher

 

Technical Support: If you have any technical problems or playback issues email us at contactus@paradigmmc.com.

 

In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.

 

Grant/Research Support: AbbVie Inc.; Amgen Inc; UCB, Inc.

Retained Consultant: AbbVie Inc.; Amgen Inc; Boehringer Ingelheim Pharmaceuticals, Inc; Celgene Corporation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc; Sun Pharmaceutical Industries Ltd; UCB, Inc

 

Retained Consultant: AbbVie Inc; Amgen Inc; Bristol-Myers Squibb Company; Eli Lilly and Company; Janssen Pharmaceuticals, Inc; Novartis Pharmaceuticals Corporation; Pfizer Inc

 

Grant/Research Support: Novartis Pharmaceuticals Corporation; Pfizer Inc

Retained Consultant: Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation; Pfizer Inc; Takeda Pharmaceutical Company Ltd
 

Indiana University School of Medicine staff members have no financial relationships to disclose.
 

Paradigm Medical Communications, LLC, staff members have no financial relationships to disclose.

Independent peer reviewer has no financial relationships to disclose.

 

Resolution of Conflict of Interest
Indiana University School of Medicine and Paradigm Medical Communications, LLC, has implemented a system to resolve conflicts of interest for each CME activity to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.

 

This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Indiana University or Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

 

As ACCME-accredited providers, Indiana University School of Medicine and Paradigm Medical Communications, LLC, activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Indiana University or Paradigm Medical Communications, LLC.

 

The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the Faculty, and do not necessarily represent those of Indiana University School of Medicine or Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Indiana University School of Medicine or Paradigm Medical Communications, LLC. Indiana University School of Medicine and Paradigm Medical Communications, LLC, accepts no liability for the content referenced in this activity.

 

Indiana University School of Medicine and Paradigm Medical Communications, LLC, are committed to protecting the privacy of those who participate in the activities (herein referred to as “website") located at www.paradigmmc.com. The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

 

This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

 

The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Indiana University School of Medicine and Paradigm Medical Communications, LLC, to continuously improve the learning experience.

 

Indiana University School of Medicine and Paradigm Medical Communications, LLC, do not transfer, sell, or share personal information with outside parties. Indiana University School of Medicine and Paradigm Medical Communications, LLC, will not otherwise disclose personal information unless required to in a legal process. Indiana University School of Medicine and Paradigm Medical Communications, LLC, staff members review individual test results to the extent necessary to record and track participants’ credits.

 

Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.

 

© 2017 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.